[{"id":"f4b4cbe0-4811-4846-aa3a-c12b65f5b2a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06052618","created_at":"2023-09-25T14:10:30.120Z","updated_at":"2025-02-25T12:29:50.276Z","phase":"Phase 2","brief_title":"Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)","source_id_and_acronym":"NCT06052618","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vonjo (pacritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 02/27/2025","start_date":" 02/27/2025","primary_txt":" Primary completion: 01/01/2033","primary_completion_date":" 01/01/2033","study_txt":" Completion: 01/01/2034","study_completion_date":" 01/01/2034","last_update_posted":"2025-02-24"},{"id":"688b0cd4-fc6d-4c69-8add-f04838298a5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05491226","created_at":"2022-08-08T12:59:06.885Z","updated_at":"2025-02-25T13:41:10.335Z","phase":"Phase 2","brief_title":"Reinvigorating TNBC Response to Immunotherapy with Combination Myeloid Inhibition and Radiation","source_id_and_acronym":"NCT05491226","lead_sponsor":"Stephen Shiao","biomarkers":" HER-2 • PD-L1","pipe":"","alterations":" ","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Niktimvo (axatilimab-csfr)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 11/17/2023","start_date":" 11/17/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"91fb4f60-829a-4224-bfce-3668ff6fda2a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04771520","created_at":"2021-02-25T15:52:21.802Z","updated_at":"2025-02-25T14:15:51.905Z","phase":"Phase 2","brief_title":"Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors","source_id_and_acronym":"NCT04771520","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 01/20/2021","start_date":" 01/20/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-17"},{"id":"569368a9-e762-49bc-b3b0-d10e7bc1381f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02390752","created_at":"2021-01-18T11:23:54.887Z","updated_at":"2025-02-25T16:58:46.439Z","phase":"Phase 1","brief_title":"Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...","source_id_and_acronym":"NCT02390752","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Turalio (pexidartinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 04/29/2015","start_date":" 04/29/2015","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-03"},{"id":"de3b1a71-0b74-42e6-87b8-569689ad09da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03153410","created_at":"2025-02-25T16:06:15.779Z","updated_at":"2025-02-25T16:06:15.779Z","phase":"Phase 1","brief_title":"Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas","source_id_and_acronym":"NCT03153410","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • LY3022855"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 09/27/2018","start_date":" 09/27/2018","primary_txt":" Primary completion: 03/09/2022","primary_completion_date":" 03/09/2022","study_txt":" Completion: 08/29/2023","study_completion_date":" 08/29/2023","last_update_posted":"2025-01-09"},{"id":"9b80d640-ac33-4411-ad4d-9614359a1e32","acronym":"","url":"https://clinicaltrials.gov/study/NCT02265536","created_at":"2025-07-19T14:00:09.317Z","updated_at":"2025-07-19T14:00:09.317Z","phase":"Phase 1","brief_title":"A Study of LY3022855 In Participants With Breast or Prostate Cancer","source_id_and_acronym":"NCT02265536","lead_sponsor":"Eli Lilly and Company","biomarkers":" CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • IL2 • ICOS • IL10 • CD14 • FOXP3 • IL1B","pipe":"","alterations":" ","tags":["CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • IL2 • ICOS • IL10 • CD14 • FOXP3 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY3022855"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 11/03/2017","primary_completion_date":" 11/03/2017","study_txt":" Completion: 11/03/2017","study_completion_date":" 11/03/2017","last_update_posted":"2024-10-28"},{"id":"f33d52c2-9a8f-4b5c-acef-4121e6304fc8","acronym":"CA209-982","url":"https://clinicaltrials.gov/study/NCT03583086","created_at":"2021-01-18T17:37:36.257Z","updated_at":"2025-02-25T14:27:15.271Z","phase":"Phase 1/2","brief_title":"Phase I/II Eval Safety \u0026 Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors","source_id_and_acronym":"NCT03583086 - CA209-982","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" EGFR • PD-L1 • BRAF • ROS1","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • BRAF • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Fumena (vorolanib)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 07/10/2018","start_date":" 07/10/2018","primary_txt":" Primary completion: 02/21/2024","primary_completion_date":" 02/21/2024","study_txt":" Completion: 04/27/2024","study_completion_date":" 04/27/2024","last_update_posted":"2024-10-08"},{"id":"6d0b40ae-0057-41ed-9ea5-d6965f8e7aa0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03238027","created_at":"2021-01-18T16:00:03.519Z","updated_at":"2024-07-02T16:35:03.052Z","phase":"Phase 1","brief_title":"A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors","source_id_and_acronym":"NCT03238027","lead_sponsor":"Syndax Pharmaceuticals","biomarkers":" PD-1 • IFNG • IL6 • TNFA • PD-L2 • IL2 • IL10 • CSF1R • IL1B • MSR1","pipe":"","alterations":" ","tags":["PD-1 • IFNG • IL6 • TNFA • PD-L2 • IL2 • IL10 • CSF1R • IL1B • MSR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Niktimvo (axatilimab-csfr)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2017","start_date":" 09/01/2017","primary_txt":" Primary completion: 11/20/2020","primary_completion_date":" 11/20/2020","study_txt":" Completion: 11/20/2020","study_completion_date":" 11/20/2020","last_update_posted":"2024-05-17"},{"id":"9f4d4138-2575-46b3-8cf6-894603dcfc63","acronym":"","url":"https://clinicaltrials.gov/study/NCT04908176","created_at":"2021-06-01T17:53:25.780Z","updated_at":"2024-07-02T16:35:07.927Z","phase":"Phase 1","brief_title":"A Drug-drug Interaction Study of Avapritinib and Midazolam","source_id_and_acronym":"NCT04908176","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib) • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 08/24/2022","start_date":" 08/24/2022","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 04/12/2024","study_completion_date":" 04/12/2024","last_update_posted":"2024-04-23"},{"id":"46bd478e-b8d0-4e9c-a5fd-b1d6d75d3215","acronym":"","url":"https://clinicaltrials.gov/study/NCT02975700","created_at":"2021-01-18T14:37:44.830Z","updated_at":"2024-07-02T16:35:10.337Z","phase":"","brief_title":"A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma","source_id_and_acronym":"NCT02975700","lead_sponsor":"Daiichi Sankyo Co., Ltd.","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Turalio (pexidartinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 01/31/2017","start_date":" 01/31/2017","primary_txt":" Primary completion: 08/31/2018","primary_completion_date":" 08/31/2018","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-04-10"},{"id":"9b0dc769-7e69-4597-ba4b-209925af9306","acronym":"","url":"https://clinicaltrials.gov/study/NCT02891603","created_at":"2021-01-18T14:11:34.890Z","updated_at":"2024-07-02T16:35:12.946Z","phase":"Phase 1/2","brief_title":"A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression","source_id_and_acronym":"NCT02891603","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" IL6 • HLA-DRB1 • CD4 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["IL6 • HLA-DRB1 • CD4 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • Vonjo (pacritinib)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 06/08/2017","start_date":" 06/08/2017","primary_txt":" Primary completion: 01/28/2022","primary_completion_date":" 01/28/2022","study_txt":" Completion: 04/18/2022","study_completion_date":" 04/18/2022","last_update_posted":"2024-03-25"},{"id":"dfb86429-181f-4825-ac3d-e1a521a067ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT03927105","created_at":"2021-01-18T19:20:59.843Z","updated_at":"2025-02-25T14:28:20.534Z","phase":"Phase 2","brief_title":"Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma","source_id_and_acronym":"NCT03927105","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cabiralizumab (BMS-986227)"],"overall_status":"Completed","enrollment":" Enrollment 4","initiation":"Initiation: 04/25/2019","start_date":" 04/25/2019","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 07/06/2023","study_completion_date":" 07/06/2023","last_update_posted":"2024-03-18"},{"id":"c372b4b4-4bc4-4fd8-9862-9add8d9bb685","acronym":"","url":"https://clinicaltrials.gov/study/NCT03922100","created_at":"2021-01-18T19:17:47.256Z","updated_at":"2024-07-02T16:35:18.417Z","phase":"Phase 1/2","brief_title":"Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML","source_id_and_acronym":"NCT03922100","lead_sponsor":"Nerviano Medical Sciences","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NMS-088"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 04/03/2019","start_date":" 04/03/2019","primary_txt":" Primary completion: 12/28/2025","primary_completion_date":" 12/28/2025","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2024-02-21"},{"id":"72b6e296-999e-4af6-965d-02f44a6823a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05039892","created_at":"2021-09-10T16:57:16.515Z","updated_at":"2024-07-02T16:35:21.555Z","phase":"Phase 2","brief_title":"Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma","source_id_and_acronym":"NCT05039892","lead_sponsor":"3D Medicines (Beijing) Co., Ltd.","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e segigratinib (3D185)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-01-31"},{"id":"3b472c71-761b-4c06-a89b-3a6142cd7c02","acronym":"AVIATOR2020","url":"https://clinicaltrials.gov/study/NCT04927260","created_at":"2021-06-15T17:53:23.444Z","updated_at":"2024-07-02T16:35:25.233Z","phase":"","brief_title":"French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients","source_id_and_acronym":"NCT04927260 - AVIATOR2020","lead_sponsor":"Centre Leon Berard","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA D842V","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA D842V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/31/2021","start_date":" 03/31/2021","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-12-25"},{"id":"a3182ec5-ccb1-442e-a4cc-96f753025ed6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05705505","created_at":"2023-01-30T15:59:40.879Z","updated_at":"2024-07-02T16:35:26.447Z","phase":"Phase 1/2","brief_title":"Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies","source_id_and_acronym":"NCT05705505","lead_sponsor":"Onconova Therapeutics, Inc.","biomarkers":" PGR","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • narazaciclib (HX301)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/29/2023","start_date":" 03/29/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2023-12-12"},{"id":"5a3f91fc-1205-487d-92df-2b35d3f75bbe","acronym":"SHIELD-1","url":"https://clinicaltrials.gov/study/NCT03993873","created_at":"2021-01-18T19:38:12.132Z","updated_at":"2024-07-02T16:35:28.600Z","phase":"Phase 1/2","brief_title":"Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET","source_id_and_acronym":"NCT03993873 - SHIELD-1","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation • MET mutation • MET fusion","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation • MET mutation • MET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e elzovantinib (TPX-0022)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 09/21/2019","start_date":" 09/21/2019","primary_txt":" Primary completion: 03/02/2025","primary_completion_date":" 03/02/2025","study_txt":" Completion: 03/02/2025","study_completion_date":" 03/02/2025","last_update_posted":"2023-11-20"},{"id":"ac40f894-1232-45a9-9ca4-ea12e9ccf046","acronym":"","url":"https://clinicaltrials.gov/study/NCT05731934","created_at":"2023-02-16T15:00:44.591Z","updated_at":"2024-07-02T16:35:36.101Z","phase":"Phase 1","brief_title":"The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05731934","lead_sponsor":"Hangzhou Hanx Biopharmaceuticals, Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e narazaciclib (HX301)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/15/2020","start_date":" 09/15/2020","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 03/28/2024","study_completion_date":" 03/28/2024","last_update_posted":"2023-09-22"},{"id":"1d571185-66c3-4224-a385-8f3e4c2f1022","acronym":"PATHFINDER","url":"https://clinicaltrials.gov/study/NCT03580655","created_at":"2021-01-18T17:36:58.229Z","updated_at":"2024-07-02T16:35:41.207Z","phase":"Phase 2","brief_title":"(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis","source_id_and_acronym":"NCT03580655 - PATHFINDER","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" TMB • KIT","pipe":" | ","alterations":" KIT mutation • KIT D816V","tags":["TMB • KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT D816V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 11/21/2018","start_date":" 11/21/2018","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2023-08-02"},{"id":"2b362821-228e-4647-ab9a-04854ffc8751","acronym":"","url":"https://clinicaltrials.gov/study/NCT05381753","created_at":"2022-05-19T12:57:08.164Z","updated_at":"2024-07-02T16:35:43.571Z","phase":"","brief_title":"Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World","source_id_and_acronym":"NCT05381753","lead_sponsor":"CStone Pharmaceuticals","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • Ayvakit (avapritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 08/29/2022","start_date":" 08/29/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-07-10"},{"id":"c402eaa9-bf76-4b0d-b1a4-4b7d8a779eb5","acronym":"BLU-285-3101","url":"https://clinicaltrials.gov/study/NCT04773782","created_at":"2021-02-26T12:55:17.604Z","updated_at":"2024-07-02T16:35:45.622Z","phase":"Phase 1/2","brief_title":"A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling","source_id_and_acronym":"NCT04773782 - BLU-285-3101","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" PDGFRA mutation","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 02/24/2022","start_date":" 02/24/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2023-06-15"},{"id":"25edff0a-7f77-4f28-8cdb-a05b5d2c6066","acronym":"","url":"https://clinicaltrials.gov/study/NCT05821738","created_at":"2023-04-20T14:03:53.744Z","updated_at":"2024-07-02T16:35:48.599Z","phase":"Phase 2","brief_title":"Avapritinib in CBF-AML With KIT Mutations","source_id_and_acronym":"NCT05821738","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" KIT • RUNX1 • RUNX1T1","pipe":" | ","alterations":" KIT mutation","tags":["KIT • RUNX1 • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-05-09"},{"id":"0b135f3f-be0a-43ad-bf86-0ed39a7b1f3a","acronym":"EXPLORER","url":"https://clinicaltrials.gov/study/NCT02561988","created_at":"2021-01-18T12:24:19.958Z","updated_at":"2024-07-02T16:35:53.073Z","phase":"Phase 1","brief_title":"(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies","source_id_and_acronym":"NCT02561988 - EXPLORER","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" KIT","pipe":" | ","alterations":" KIT D816V","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT D816V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 03/10/2016","start_date":" 03/10/2016","primary_txt":" Primary completion: 10/05/2022","primary_completion_date":" 10/05/2022","study_txt":" Completion: 01/19/2023","study_completion_date":" 01/19/2023","last_update_posted":"2023-03-17"},{"id":"ed108878-46a5-4e3a-93b2-f64236ea023a","acronym":"C4-MOSART","url":"https://clinicaltrials.gov/study/NCT03431948","created_at":"2021-01-18T16:55:43.382Z","updated_at":"2025-02-25T14:38:06.135Z","phase":"Phase 1","brief_title":"Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer","source_id_and_acronym":"NCT03431948 - C4-MOSART","lead_sponsor":"University of Chicago","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cabiralizumab (BMS-986227) • urelumab (BMS-663513)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 03/15/2018","start_date":" 03/15/2018","primary_txt":" Primary completion: 02/29/2020","primary_completion_date":" 02/29/2020","study_txt":" Completion: 04/11/2022","study_completion_date":" 04/11/2022","last_update_posted":"2023-02-16"}]